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ABSTRACT: 
Poly(lactic-co-glycolic acid) (PLGA) based nano/micro particles were investigated as a 25 
potential vaccine platform for pertussis antigen. Presentation of pertussis toxoid as 
nano/micro particles (NP/MP) gave similar antigen-specific IgG responses in mice 
compared to soluble antigen. Notably, in cell line based assays, it was found that PLGA 
based nano/micro particles enhanced the phagocytosis of fluorescent antigen-
nano/micro particles by J774.2 murine monocyte/macrophage cells compared to soluble 30 
antigen. More importantly, when mice were immunized with the antigen-nano/micro 
particles they significantly increased antigen-specific Th1 cytokines INF-γ and IL-17 
secretion in splenocytes after in vitro re-stimulation with heat killed Bordetalla 
pertussis, indicating the induction of a Th1/Th17 response. Also, presentation of 
pertussis antigen in a NP/MP formulation is able to provide protection against 35 
respiratory infection in a murine model. Thus, the NP/MP formulation may provide an 
alternative to conventional acellular vaccines to achieve a more balanced Th1/Th2 
immune response.  
Keywords: Pertussis; PLGA nano/micro particles; Phagocytosis; Adjuvant 
40 
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1. Introduction 
The introduction of comprehensive vaccination programmes worldwide in 1950s has 
led to the global incidence of whooping cough (pertussis) falling dramatically (Roush et 
al., 2007). Acellular vaccines (ACVs) containing purified pertussis antigens have 
replaced the traditional whole cell vaccines (WCVs) in most developed countries of the 45 
world in the 1980s/1990s due to concerns over reactogenicity of WCVs (Greco  et al., 
1996). All marketed pertussis ACVs contain detoxified pertussis toxin (PTd) with most 
containing varying doses of detoxified filamentous haemagglutinin (dFHA) and 
pertactin (d69K) or fimbrial antigens (Fim2&3). However, despite efficient vaccination 
programmes in many ACV covering countries, the incidence of pertussis is increasing 50 
in  both infants and vaccinated young adults with reported outbreaks in many countries 
including USA, Australia, Ireland and UK (Barret AS, June 2010 ; Nieves DJ, 2011; 
Spokes et al., 2010). In addition, current understanding on the mechanism of vaccine-
induced immunity, especially the role of T-cell and cell mediated immunity (CMI), and 
pertussis infection models indicate that altering the immune bias to a Th1/Th17 55 
response is beneficial for clearance of bacteria (Dunne et al., 2010; Mahon et al., 1997). 
This suggests that improving the efficacy and durability of the protection induced by 
current ACVs is of importance and development of new generation of vaccines with 
long-lasting immunity is needed for better control of this disease. There are several 
possible explanations for the short duration of protection offered by ACVs, such as 60 
incomplete antigen coverage and incorrect balance of antigens in the formulation. Most 
significantly, ACVs are widely acknowledged to be less protective than WCVs and 
require the inclusion of adjuvants that induce Th-1 cells to boost protective immunity. 
The immune response in humans induced by current ACVs with aluminium as an 
adjuvant is predominantly Th-2 type response (Gupta and Ahsan, 2011; Leroux-Roels, 65 
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2010). However, despite that aluminium can effectively induce a strong antibody 
response, it is a weak adjuvant for the induction of CMI (Mahon et al., 1997). The 
different profiles in cellular and humoral responses, macrophage activation and 
bacterial clearance of WCVs and ACVs indicated that different protective mechanisms 
are at work involving these two types of vaccine (Ausiello et al., 1997; Canthaboo et 70 
al., 2002; Mills et al., 1998; Warfel et al., 2014) . Therefore, the development of a 
vaccine which can mount both cellular and humoral responses to generate a more 
effective and long lasting immune response would be the key to improve the efficacy of 
the current ACVs.  
Biodegradable micro/nanoparticles (NP/MP) generated from poly(lactic-co-glycolic 75 
acid) (PLGA) as a delivery system have attracted much attention due to their clinically 
proven biocompatibility and adjuvant activity during immunisation protocols (Danhier 
et al., 2012; Feczkó et al., 2011). In particular, PLGA-based nano- and microparticles 
have been extensively investigated as a vaccine delivery system as well as used for 
controlled drug delivery for biopharmaceuticals (Abbas, 2008; Jiang et al., 2005; Kim 80 
et al., 2016; Santillan et al., 2011). Biodegradable particles with entrapped vaccine 
antigens, such as proteins, peptide or DNA, have recently been shown to possess 
significant potential as vaccine delivery systems. It is also known that size, charge and 
shape of particles play significant roles in antigen uptake. Both PLGA nanoparticles 
and microparticles have been investigated for vaccine delivery and demonstrated 85 
significant differences in modulating immune responses (Gregory et al., 2013; Hiremath 
et al., 2016; Johansen et al., 2000; Peyre et al., 2004; Singh et al., 2015). Nanopartilces 
are believed to promote cellular response whereas microparticles promote humoral one 
(Chong et al., 2005; Gutierro et al., 2002). However, micropartilces with a size less than 
10 µm have shown efficient internalization by macrophages (Champion et al., 2008). 90 
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Adjuvants function through three primary mechanisms: (1) protect and stabilise the 
entrapped  antigen, (2) deliver antigen more effectively to antigen presenting cells 
(APCs), and (3) act as an immunostimulant adjuvant to activate or enhance immunity. 
Particle-based antigen (Ag) delivery can potentially provide many levels of 
adjuvanticity that include: prolonging Ag residence in the body (depot formation); 95 
enhancing Ag uptake mediated by dendritic cell (DC); direct stimulation of DC and 
promotion of cross-presentation especially in cases when new vaccine applications 
require cell-mediated immunity (Rice-Ficht et al., 2010). Here we report a pilot study to 
investigate PLGA nano/micro particles as a candidate platform for the production of 
novel vaccines against pertussis that can enhance the efficacy of ACV. 100 
2. Materials and Methods 
2.1 Materials  
The pertussis toxoid was kindly donated by Serum Institute of India. Poly (lactide-co-
glycolide acid) (PLGA) (lactic acid:glycolic acid-50:50, Resomer RG 503H) was 
purchased from Evonik Industries, Germany. Albumin from bovine serum (BSA), 105 
polyvinyl alcohol (PVA, Mowiol® 4-88, Mowiol® 8-88, Mowiol® 18-88 with MW 
31,000, 67,000 & 130,000 respectively), Sodium hydroxide, sodium phosphate 
monobasic monohydrate, foetal calf serum and L-glutamine were purchased from 
Sigma-Aldrich, UK. Albumin–fluorescein isothiocyanate conjugate (BSA-FITC), 
RPMI 1640 medium, penicillin, streptomycin and AlexaFluor594-conjugated phalloidin 110 
was obtained from Life Technologies, UK. Dichloromethane was received from Fisher 
Scientific, UK. Pierce® Bicinchoninic acid protein assay reagent A and B were 
purchased from Thermo Scientific, Germany. 
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2.2 Preparation of PLGA particles encapsulated with antigens 
2.2.1 Formulation development using albumin from bovine serum (BSA) 115 
PLGA micro/nanoparticles containing BSA was prepared using double emulsion 
(w/o/w) solvent evaporation method (Feczkó et al., 2011). Briefly, appropriate amount 
of BSA (Table 1) was dissolved in deionised water and the resultant solution was 
emulsified in 5ml PLGA (200mg) dichloromethane solution by sonicating for 60 
seconds (UP200S ultrasonic processor, Hielscher Ultrasound technology, Germany) at 120 
setting 37% (54.05W electric power input) in ice bath and the primary emulsion was 
obtained. 20ml polyvinyl alcohol (PVA) solution of appropriate concentration (second 
aqueous phase, Table 1) was added into the primary emulsion and was emulsified by 
sonicating at 37% for 3 minutes using the same sonicator under the same conditions to 
obtain the second emulsion. The organic solvent in the emulsion was evaporated under 125 
magnetic stirring at 800 rpm for 2 hours in a fume cupboard under room temperature. 
The obtained BSA-loaded PLGA particles were separated from the liquid medium by 
centrifugation (T1250 Sorvall Ultracentrifuge, Thermo Fisher Scientific, Inc. USA) at 
25,000 rpm for 30 minutes. The isolated BAS-loaded PLGA particles were washed with 
deionised water and centrifuged again at 14,000 rpm for 15 minutes. The particles were 130 
then washed with deionised water for two more times without centrifugation and were 
freeze-dried (Micromodulyo freeze dryer, Mecha Tech Systems, UK) for 19 hours. The 
final particles were stored in a freezer at -20ºC.  
A range of BSA-loaded PLGA particle formulations were prepared by varying BSA 
loading ratio (% w/w BSA loading based on PLGA), PVA molecular weight, PVA 135 
concentration in the aqueous phase and the phase ratio of the organic phase vs the 
second aqueous phase (Table 1). 
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2.2.2 Preparation of final BSA-FTIC and pertussis toxoid-containing PLGA 
particles 
The final PLGA particles containing BSA-FTIC and pertussis toxoid (PTd) for use in 140 
the biological tests were prepared as described in Section 2.2.1. The BSA-FTIC orPTd 
loading ratio was 5 % (w/w); the PVA used has a molecular weight of 31,000 Da at a 
concentration of 1.75 % (w/v); and the phase ratio of the organic phase vs the second 
aqueous phase was 1:4.  
2.3 Characterisation of antigen-loaded PLGA particles 145 
2.3.1 Particle size and zeta potential measurement 
Antigen (BSA-FTIC or PTd)-loaded PLGA particles (50 mg) were dispersed in 0.1% 
(w/v) PVA solution (molecular weight 31,000 Da). The particle size and zeta potential 
were determined using Zetasizer nanoseries (Malvern instruments, Malvern, UK) at 
25ºC. When multiple peaks were present at the particle size measurement, the particle 150 
size (mean ± SD) and percentage intensity of each peak were reported.  
2.3.2 Surface morphology using scanning electron microscopy (SEM) 
The surface morphologies of the antigen-loaded PLGA particles were examined using 
SEM (JEOL JSM-35 Scanning Microscope, JEOL (UK) Ltd, UK), with an electron 
energy at 5-10 keV.  155 
2.3.3 Calculation of yield and encapsulation efficiency 
The final weight of the antigen-loaded PLGA particles after freeze-drying was weighed 
and the yield (%) of the preparation was calculated using Equation 1.  
Equation 1. 
Yield (%)=Actual weight of the particles / The cortical weight of the particles*100% 160 
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The encapsulation efficiency (%) was calculated using Equation 2.  
Equation 2 
Encapsulation efficiency (%) = Actual concentration of the antigen in the particles / 
The cortical concentration of the antigen in the particles*100% 
2.3.4 Quantification of antigen loading  165 
The antigen loading in the PLGA particles  were quantified using BCA assay. The 
loaded particles (10 mg) were suspended in 1 ml 1M sodium hydroxide (NaOH) and 
agitated at 250 rpm using an electronic shaker for 3 hours at room temperature (RT) to 
hydrolyse the polymer. 3 ml of PBS (pH 7.4) and 1ml 1M hydrochloride acid (HCl)  
were added to the PLGA-NaOH mixture. The resultant sample (0.1ml) was mixed with 170 
2 ml BCA reagent A and B (50:1). The absorbance of the above solution was measured 
using UV-Vis spectroscopy at 557 nm. Each measurement was repeated in triplication. 
A calibration curve was prepared at BSA concentrations of 20, 40, 80, 120, 160 and 200 
mg/ml.  
2.5 Culture of J774.2 cells 175 
Murine monocyte/macrophage J774.2 cells were maintained at 37°C under the presence 
of 5% CO2 in complete RPMI (cRPMI) comprising RPMI 1640 medium, 10% foetal 
calf serum, 10 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin.   
2.6 Uptake of PLGA nano/micro particles by J774.2 cells  
2.6.1 Flow cytometry 180 
A quantity of 106 J774.2 cells was seeded in each well of a 24-well tissue-culture plate 
and incubated for 2 h at 37oC in 5% CO2.  Subsequently 1 ml of fresh cRPMI was 
added to each well to replace the medium. Particles loaded with 50% BSA-FITC or 
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soluble BSA-FITC were dispersed in cRPMI to prepare a 10mg/ml suspension . A 0.5 
ml aliquot of the suspension was added to each well and incubated for 60 min at 37oC, 185 
in 5% CO2 whilst protected from light. The uptake was terminated by washing the cells 
twice with ice-cold PBS. The cells were then re-suspended in ice-cold PBS (1 ml) and 
centrifuged for 10 min at 118 g. The resultant pellet was re-suspended in 4 ml fixing 
solution (1% formaldehyde in PBS) and samples were stored at 4°C under protection 
from light. A FACS Canto II flow cytometer (BD Biosciences) was used to determine 190 
the uptake of fluorescent particles.  
2.6.2 Confocal laser-scanning microscopy  
Two mililiter of 106 J774.2 cells in cRPMI was added to each well of a 24-well plated 
containing  0.2% gelatine (in PBS) coated sterile glass coverslips and incubated for 3h 
at 37oC in5% CO2. Following incubation, appropriate antigen formulation was added 195 
and incubated for a further hour. After washing the cells twice with PBS-A (without Ca 
and Mg),  a fixing solution (4% paraformaldehyde in PBS-A, 300 µl/well) was added 
and the cells were incubated for 20 min at room temperature (RT). Cells were washed 
as before.  To permeabilise the cells, 300µl of PBS-A containing 0.2% BSA and 0.2% 
TritonX-100 was added to each well and incubated for 15 min at RT without shaking. 200 
Following washing, to block non-specific binding, 300µl of blocking reagent (PBS-A 
containing 5% BSA ) was added to each well and incubated for 1 h at RT without 
shaking. Once washed, AlexaFluor594-conjugated phalloidin  was used to stain the 
actin cytoskeleton for 5 min and subsequently  4,6-diamidino-2-phenylindole (DAPI) 
were applied for nuclear staining for 3 min. The fluorescent cells were visualised using 205 
an NA 1.25 oil immersion lens on a laser-scanning confocal microscope (Leica SP2 
AOBS) . Images were analysed using IMARIS software v7.4.2 (Bitplane, Switzerland).  
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2.7 Immunisation of mice 
The required doses of PTd NP/MP formulations were re-suspended in sterile PBS 
immediately prior to immunisation. Groups of 5 female NIH mice (6-8 week old, 210 
Envigo, UK) were injected subcutaneously with 0.5 ml desired formulation at days 0 
and 28. A further group of five mice were immunised with PBS as negative control. 
Mice were sampled for sera at four weeks after primary immunisation and two weeks 
post-boost.  
2.8 Antigen-specific serum IgG titres 215 
Antibody response of the formulations was determined using antigen specific ELISA as 
described previously (Cheung et al., 2006) . Total antigen-specific IgG titres were 
determined relative to First International Reference Serum for pertussis (97/642, 
NIBSC, UK).  
2.9 Protection studies by respiratory challenge 220 
Two weeks after the second dose of immunisation, groups of 10 mice were subjected to 
aerosol challenge with a  suspension of 108 cfu/ml B. pertussis 18.323 in 1% (w/v) 
casamino acids solution containing 0.6% w/v NaCl as described previously (Xing et al., 
1999). Successful infection was confirmed in 5 mice from the negative control group at 
2 h post-infection. At 7 d post-infection, the lungs and trachea from remaining mice 225 
were removed and homogenized in 1 ml casamino acids solution. Serial dilutions of the 
homogenate were plated onto charcoal agar (Oxoid) plates containing 10% (v/v) 
defibrinated horse blood (Oxoid) to perform viable counts. The numbers were 
expressed as CFU/lungs and trachea with a detection limit of 50 CFU/mouse.  
2.10 In vitro assays for cytokines from immune cells  230 
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Spleenocytes from immunised mice were placed in 24-well tissue culture plates (4 x106 
cells/well) and cultured with or without heat-killed B. pertussis cells (5 x 107 
/well)(Xing et al., 1998). Cell supernatants were collected and screened for cytokine 
responses.   Initial cytokine screening was done by BD Cytometric Bead Array for 7 
cytokines: interleukin-6 [IL-6], IL-2, IL-4, IL-17 and IL-10, tumor necrosis factor alpha 235 
[TNF-alpha], gamma interferon [IFN-gamma](BD Biosciences) according to the 
manufacturer’s recommended procedure. After initial screening, for further 
experiments, selected cytokine (IL-17 and IFN-γ) responses in cell supernatants were 
determined by an ELISA method using DuoSet kit (R&D Systems).   
2.11 Statistical analysis  240 
Statistical analysis was performed using Combistat software Version 4.0, EDQM. 
Student’s t-tests were performed to compare two groups with a. statistical significance 
defined as p<0.05.  
2.12 Ethical approval  
Ethical approval was obtained for all animal experiments from the Ethical Committee 245 
of National Institute for Biological Standards and Control, UK. All experiments were 
regulated according to the Animal Scientific Procedures Act (1986), UK.   
 
3. Results 
3.1 Charateristics of antigen-loaded PLGA particles 250 
The yield and encapsulation efficiency of BSA-containing PLGA particles produced 
during the formulation development are shown in Table 1. F9 has achieved the highest 
yield, antigen loading, and encapsulation efficiency and was selected as the formulation 
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to produce the final BSA-FTIC and PTd loaded PLGA particles. The characteristics of 
the final BSA-FTIC and PTd loaded PLGA particles are shown in Table 2. The 255 
obtained antigen-loaded PLGA particles are a mixture of nanoparticles and 
microparticles exhibiting particle sizes in two size ranges (Table 2). Fig. 1 shows that 
the BSA-loaded PLGA particles are spherical with smooth surfaces.  
3.2 Antigen phagocytosis by J774.2 cells 
FITC-BSA was used as a model antigen to investigate NP/MP uptake by both 260 
Fluorescence-activated cell sorting (FACS) and confocal microscopy. J774.2 murine 
macrophages were incubated with 120ug/ml FITC-BSA in soluble or particle 
formulation for 3h and 24h for analysis by confocal microscopy and FACS 
respectively. Fig.2 A-C shows the uptake of fluorescent antigen using confocal laser-
scanning microscopy  quantified by flow cytometry (panels D-E). Fig.2 A and D serve 265 
as control. It is evident that J774.2 cells contained low levels of fluorescence indicating 
soluble BSA-FITC was poorly phagocytosed (Fig. 2B). In contrast, punctate regions of 
green fluorescence were displayed in cells treated with NP/MP formulation suggesting 
enhanced FITC-BSA uptake by macrophages (Fig.2 C). These observations were 
confirmed by flow cytometry.  The cells that were exposed to BSA-FITC NP/MPs 270 
exhibited enhanced phagocytosis with an increase in both the number of fluorescent 
cells and fluorescence intensity (Fig. 2D and 2E), showing an increase in MedFI of the 
P2-gated population (Fig.2E).  
3.3 Antibody responses  
Subcutaneous injection of mice with PTd encapsulated NP/MP formulation induced 275 
similar or slightly lower anti-PT IgG titres compared with the soluble antigen at 
equivalent dose at both 28  and 42 d (Fig.3). Immunisation with both the soluble and the 
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NP/MP formulations gave good booster response which indicates memory response. 
However, neither the antigen-specific IgG titres nor the duration of antibody response 
were altered by the NP/MP formulation indicating that it did not have adjuvant effect on 280 
PT antibody responses in vivo.  
3.4 Antigen-specific cytokine profile 
To investigate the type of cytokine produced in the spleen cell supernatants, mice were 
immunised with soluble PTd or PTd-NP/MP formulations. Cytokine production profile 
after in vitro stimulation with heat killed cells (HKC) was first screened using BD 285 
Cytometric Bead Array for 7 cytokines: IL-6, IL-2, TNF-alpha, IFN-gamma, IL-4, IL-
17 and IL-10. In general, the spleen supernatants from mice immunised with soluble 
PTd and PTd-NP/MP induced similar levels of TNF-alpha, IL-10. Less significantly 
increased induction of IL-4 and IL-6, and a slightly decreased in IL-2 level was 
observed in the NP/MP group (data not shown). The most significantly increased levels 290 
in Th1 type cytokines IFN-gamma () and IL-17 cytokines were observed in the PTd -
P/MP immunised group. To further confirm this, in latter experiments, sandwich ELISA 
was used to determine the levels of IFN- and IL-17 in spleen supernatants after in-vitro 
re-stimulation with HKC. Fig 4 shows spleen cell supernatants from mice that received 
PTd-NP/MP formulation had significantly higher levels (>4 folds, p <0.05) of IFN- 295 
and IL-17 production than the soluble antigen group.  
3.5. Protective effect of PTd NP/MP formulation in an aerosol infection 
model 
The protective effect of PTd NP/MP formulation against the infection was investigated 
in an aerosol challenge model. Under the current immunisation dose, an approximately 300 
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10% reduction in CFU was found in the soluble PTd group in comparison to PBS 
control group. PTd in NP/MP formulation group showed similar results with a further 
~5% reduction in CFU although this did not reach statistical significance (Fig.5) 
between these two groups. 
 305 
4 Discussion 
In the last two decades, pertussis has resurged in different countries. In particular 
significant mortality in infants were caused by  large outbreaks in US, Australia, UK 
and The Netherlands in the 2010–2013 period,(Black RE, 2010; Cherry, 2010).  The 
epidemiological situation of pertussis is possibly to be related to suboptimal or waning 310 
immunity induced by ACV (Klein  et al., 2012) . This points out the urgent need to 
design and develop new vaccine formulation with high effectiveness in conferring 
protective immunity. In this study, we used biodegradable polymers as vaccine carriers 
to explore their ability to promote both Th1 and Th-17 cells immune responses for 
pertussis.  315 
The yield and encapsulation efficiency of the PLGA particles are extremely important 
for incorporating valuable protein antigens such as pertussis toxoid (PTd), and the 
capacity of antigen loading determines the volume of the final vaccine product. 
Formulation parameters, including PVA molecular weight, PVA concentration and the 
phase ratio, were found to affect the loading capacity, yield and encapsulation 320 
efficiency of the final particles using the double emulsion solvent evaporation method, 
in agreement with published studies (Bilati et al., 2005; Feczkó et al., 2011). The 
optimised formulation was able to successfully incorporate PTd with high loading, yield 
and encapsulation efficiency. The PTd-loaded PLGA particles showed dual-sized 
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characteristics, as a mixture of nanoparticles (size range 200-300 nm) and 325 
microparticles (size ~5 µm). Both PLGA nanoparticles and microparticles as vaccine 
delivery have been reported to show differences in modulating cellular or humoral 
immune responses (Gutierro, Hernández et al. 2002, Chong, Cao et al. 2005, Champion, 
Walker et al. 2008). An in vitro study demonstrated that PLGA microparticles (5-7 µm) 
were attached to cell membrane and required more time to be engulfed by the 330 
macrophages compared to nano-sized particles, which led to more potent inflammatory 
stimulus after the uptake process (Nicolete et al., 2011). Therefore, it is difficult to 
predict the immune response by using either micro- or nanoparticles of PLGA as 
antigen carriers. In this pilot study, the combination of nanoparticles and microparticles 
were applied for in vitro and in vivo investigations to demonstrate the potential of 335 
PLGA based particles for enhanced PTd delivery. Further separation of the particle 
sizes and investigation into their distinct effects will be the subject of future research.  
Humoral immunity was shown to be critical for optimum protection against B. pertussis 
infection together with cell-mediated immunity; long term immunity is effectively 
maintained bymemory T and B cells and the highest level of protection is associated 340 
with  the Th1 subtype (Mills et al., 1998). Antigens entrapped PLGA particles, when 
delivered parenterally,was found to stimulate cell-mediated immune responses (Moore 
et al., 1995) and PTd with another pertussis antigen FHA entrapped in biodegradable 
polymer particles have been reported to elicit a potent type 1 T cell  and antibody 
response (Conway et al., 2001). In the present study, INF-γ level from mice immunized 345 
with PTd NP/MP were greatly enhanced. The MP/NP incorporated antigen showed 
ability to shift the T cell response from Th2 or mixed Th1/Th2 to Th1, which is 
consistent with above literature reports. This is further supported by the uptake and 
presentation of particulate antigen by phagocytic cellswhich are thought to act as 
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antigen presenting cells (APC) for Th1 response (Gajewski TF, 1991). In deed, great 350 
enhancement of phagocytosis for NP/MP formulation by macrophages was observed in 
this study and this was in agreement with previous reports that INF-γ producing cells 
could activate macrophages to kill intracellular bacteria and thus play a critical role in 
protection against B. pertussis during primary infection (Barbic et al., 1997; Mahon et 
al., 1997)  355 
While NP/MP formulations were found to have an effect on INF-γ producing cells, to 
our knowledge, effect of PTd NP/MP on Th17 cells has not been addressed so far. It 
was in recent years that the important role of Th17 cells in clearing pathogens during 
host defense reactions have attracted much attention (Korn et al., 2009). In a non-
human primates study, it was found that ACV vaccinated animals exhibited a Th1/Th2 360 
response; however, previously infected animals and animals that were vaccinated using 
conventional whole cell pertussis possess strong B. pertussis-specific T helper 17 
(Th17) memory as well as Th1 memory (Warfel et al., 2014). Th17 cells were also 
reported to be involved in adaptive immunity to other pathogens e.g. Pseudomonas 
aeruginosa, Staphylococcus aureus (Lin et al., 2009; Priebe et al., 2008). Here we 365 
demonstrate that IL-17 secretion was significantly enhanced in the spleen cell culture 
from mice immunized with PTd NP/MP formulation which indicate that the NP/MP 
formulations were able to have enhancement effect on INF-γ as well as IL-17 producing 
cells. According to previous report,  IL-17, especially IL-17A, and  IFN- γ can promote 
macrophage killing of B. pertussis (Ross et al., 2013; Sarah C. Higgins, 2006) . 370 
It has been reported that immunity of children who had received 5 doses of ACV wanes 
substantially each year (Klein  et al., 2012) . Biodegradable NP/MP could have 
potential to avoid this problem by providing controlled antigen release from the 
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micro/nanoparticles which is resultant by efficient phagocytosis and transportation to 
the lymph nodes (Gray and Skarvall, 1988).  375 
In conclusion, these preliminary results suggested that NP/MP formulation could 
promote protective immunity both Th1 and Th-17 responses of pertussis antigen, which 
may enhance vaccine protective efficacy. NP/MP could be a potential candidate 
platform for the development of novel vaccines against pertussis. 
 380 
Acknowledgements 
We thank Mrs Sharon Tierney on the advice of data analysis. We appreciate the advice 
and direction from Mr. Alan Greig and Dr. See-Wai Lavelle on the performance of 
Laser Confocal microscope and Flow cytometry. 
 385 
 
Funding 
This work was supported by the National Natural Science Foundation of China 
(81301309, and 51373199), the British Council Innovation Initiative Award to Bing 
Song, and Innovative Research Team on Immunobiomaterials in Peking Union Medical 390 
College. 
  
Author’s contribution: 
Page 18 of 26 
The concept and design of the study was done by Dorothy Xing, Xiaoqing Wei, and 
Bing Song. The experiments, acquisition of data, analysis and interpretation of data 395 
were done by Pan Li, Catpagavalli Asokanathan, Fang Liu, Kyi Kyi Khaing, and 
Dorota Kmiec. Pan Li, Catpagavalli Asokanathan, Fang Liu, Dorothy Xing and Deling 
Kong contributed to the manuscript writing. Deling Kong made the submission.
Page 19 of 26 
References: 
Abbas A.O., Donovan M.D., Salem A.K., 2008. Formulating Poly(Lactide-Co-400 
Glycolide) Particles for Plasmid DNA Delivery. J. Pharm. Sci. 97: 2448-2461. 
Ausiello C.M., Urbani F., la Sala A., Lande R., Cassone A., 1997. Vaccine- and 
antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of 
infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65: 2168-2174. 
Barbic J., Leef M.F., Burns D.L., Shahin R.D., 1997. Role of gamma interferon in 405 
natural clearance of Bordetella pertussis infection." Infect. Immun. 65: 4904-4908. 
Barret A.S., Breslin A., Cullen L., Murray A., Grogan J., Bourke S., Cotter S., 2010.  
Pertussis outbreak in northwest Ireland, January – June 2010. Euro Surveill. 15: 
pii=19654. 
Bilati U., Allémann E., Doelker E., 2005. Poly(D,L-lactide-co-glycolide) protein-loaded 410 
nanoparticles prepared by the double emulsion method—processing and formulation 
issues for enhanced entrapment efficiency. J. Microencapsul. 22: 205-214. 
Black R.E., Johnson H.L., Lawn J.E., Rudan Bassani D.G., Jha P., Campbell H., 
Walker C.F., Cibulskis R., Eisele T., Liu L., Mathers C., 2010. Child Health 
Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national 415 
causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969-1987. 
Canthaboo C., Xing D., Wei X.Q., Corbel M.J., 2002. Investigation of Role of Nitric 
Oxide in Protection from Bordetella pertussis Respiratory Challenge. Infect. Immun. 
70: 679-684. 
Champion J.A., Walker A., Mitragotri S., 2008. Role of Particle Size in Phagocytosis of 420 
Polymeric Microspheres. Pharm. Res. 25: 1815-1821. 
Page 20 of 26 
Cherry, J. D., 2010. The Present and Future Control of Pertussis. Clin. Infect. Dis. 51: 
663-667. 
Cheung G.Y., Xing D., Prior S., Corbel M.J., Parton R., Coote J.G., 2006. Effect of 
Different Forms of Adenylate Cyclase Toxin of Bordetella pertussis on Protection 425 
Afforded by an Acellular Pertussis Vaccine in a Murine Model. J. Control. Rel. 74: 
6797-6805. 
Chong C.S., Cao M., Wong W.W., Fischer K.P., Addison W.R., Kwon G.S., Tyrrell 
D.L., Samuel J., 2005. "Enhancement of T helper type 1 immune responses against 
hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery." J. Control. Rel. 430 
102: 85-99.  
Conway M.A., Madrigal-Estebas L., McClean S., Brayden D.J., Mills K.H., 2001. 
"Protectio- n against Bordetella pertussis infection following parenteral or oral 
immunization with antigens entrapped in biodegradable particles: effect of formulation 
and route of immunization on induction of Th1 and Th2 cells." Vaccine 19: 1940-1950. 435 
Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V., 2012. "PLGA-
based nanoparticles: An overview of biomedical applications." J. Control. Release 161: 
505-522 . 
Dunne A., Ross P.J., Pospisilova E., Masin J., Meaney A., Sutton C.E., Iwakura Y., 
Tschopp J., Sebo P., Mills K.H., 2010. "Inflammasome Activation by Adenylate 440 
Cyclase Toxin Directs Th17 Responses and Protection against Bordetella pertussis." J. 
Immunol. 185: 1711-1719 . 
Feczkó, T., J. Tóth, Dósa G., Gyenis J., 2011. "Optimization of protein encapsulation in 
PLGA nanoparticles." Chem. Eng. Process.: Process Intensif. 50: 757-765 . 
Page 21 of 26 
Gajewski T.F., P. M., Wong T., Fitch F.W., 1991. "Murine Th1 and Th2 clones 445 
proliferate optimally in response to distinct antigen-presenting cell populations." J. 
Immunol. 146:1750-8 . 
Gray, D. and Skarvall H., 1988. "B-cell memory is short-lived in the absence of 
antigen." Nature 336: 70-73 . 
Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., Ciofi 450 
degli Atti M.L., Giammanco A., Panei P., Blackwelder W.C., Klein D.L., Wassilak 
S.G., 1996 "A Controlled Trial of Two Acellular Vaccines and One Whole-Cell 
Vaccine against Pertussis." New Engl. J. Med. 334: 341-349 . 
Gregory A.E., Titball R., Williamson D., 2013. "Vaccine delivery using nanoparticles." 
Front. Cell. Infect. Microbiol. 3. doi: 10.3389/fcimb.2013.00013. 455 
Gupta, V., Ahsan F., 2011. "Influence of PEI as a Core Modifying Agent on PLGA 
Microspheres of PGE(1), A Pulmonary Selective Vasodilator." Int. J. Pharm. 413: 51-
62 . 
Gutierro I., Hernández R.M., Igartua M., Gascón A.R., Pedraz J.L., 2002. "Size 
dependent immune response after subcutaneous, oral and intranasal administration of 460 
BSA loaded nanospheres." Vaccine 21: 67-77 . 
Hiremath J., Kang K.I., Xia M., Elaish M., Binjawadagi B., Ouyang K., Dhakal S., 
Arcos J., Torrelles J.B., Jiang X., Lee C.W., Renukaradhya G.J., 2016. "Entrapment of 
H1N1 Influenza Virus Derived Conserved Peptides in PLGA Nanoparticles Enhances T 
Cell Response and Vaccine Efficacy in Pigs." PLoS ONE 11: e0151922. doi:10.1371/ 465 
journal.pone.0151922. 
Page 22 of 26 
Jiang W., Gupta R.K., Deshpande M.C., Schwendeman S.P., 2005. "Biodegradable 
poly (lac- tic-co-glycolic acid) microparticles for injectable delivery of vaccine 
antigens." Adv. Drug Deliv. Rev. 57: 391-410 . 
Johansen P., Men Y., Merkle H.P., Gander B., 2000. "Revisiting PLA/PLGA 470 
microspheres: an analysis of their potential in parenteral vaccination." Eur. J. Pharm. 
Biopharm. 50: 129-146 . 
Kim Y.K., Shin J.S., Nahm M.H., 2016. "NOD-Like Receptors in Infection, Immunity, 
and Diseases." Yonsei. Med. J. 57: 5-14 . 
Klein N.P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R., 2012. "Waning 475 
Protection after Fifth Dose of Acellular Pertussis Vaccine in Children." N. Engl. J. 
Med. 367: 1012-1019 . 
Korn T., Bettelli E., Oukka M., Kuchroo V.K., 2009. "IL-17 and Th17 Cells." Annu. 
Rev. Immunol. 27: 485-517 . 
Leroux-Roels G., 2010. "Unmet needs in modern vaccinology: Adjuvants to improve 480 
the immune response." Vaccine. 28: C25-C36 . 
Lin L., Ibrahim A.S., Xu X., Farber J.M., Avanesian V., Baquir B., Fu Y., French S.W., 
Edwards J.E. Jr., Spellberg B., 2009. "Th1-Th17 Cells Mediate Protective Adaptive 
Immunity against Staphylococcus aureus and Candida albicans Infection in Mice." 
PLoS Pathog. 5: e1000703 . doi: 10.1371/journal.ppat.1000703. 485 
Mahon B.P., Sheahan B.J., Griffin F., Murphy G., Mills K.H., 1997. "Atypical Disease 
after Bordetella pertussis Respiratory Infection of Mice with Targeted Disruptions of 
Interferon-γ Receptor or Immunoglobulin μ Chain Genes." J. Exp. Med. 186: 1843-
1851 . 
Page 23 of 26 
Mills K.H., Ryan M., Ryan E., Mahon B.P., 1998. "A Murine Model in Which 490 
Protection Correlates with Pertussis Vaccine Efficacy in Children Reveals 
Complementary Roles for Humoral and Cell-Mediated Immunity in Protection against 
Bordetella pertussis." Infect. Immun. 66: 594-602 . 
Moore A., McGuirk P., Adams S., Jones W.C., McGee J.P., O'Hagan D.T., Mills K.H., 
1995. "Immunization with a soluble recombinant HIV protein entrapped in 495 
biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and 
CD4+ Th1 cells." Vaccine 13: 1741-1749. 
Nicolete R., dos Santos D.F., Faccioli L.H., 2011. "The uptake of PLGA micro or 
nanoparticles by macrophages provokes distinct in vitro inflammatory response." Int. 
Immunopharmacol. 11: 1557-1563 . 500 
Nieves D.J., S. J., Ashouri N., McGuire T., Adler-Shohet F.C., Arrieta A.C., 2011. 
"Clinical and laboratory features of pertussis in infants at the onset of a California 
epidemic." J. Pediatr. 159: 1044-1046 .  
Peyre M., Audran R., Estevez F., Corradin G., Gander B., Sesardic D., Johansen P., 
2004. "Childhood and malaria vaccines combined in biodegradable microspheres 505 
produce immunity with synergistic interactions." J. Control. Release 99: 345-355 . 
Priebe G.P., Walsh R.L., Cederroth T.A., Kamei A., Coutinho-Sledge Y.S., Goldberg 
J.B., Pier G.B., 2008. "IL-17 Is a Critical Component of Vaccine-induced Protection 
against Lung Infection by LPS-heterologous Strains of Pseudomonas aeruginosa." J. 
Immunol. 181: 4965-4975 . 510 
Rice-Ficht A.C., Arenas-Gamboa A.M., Kahl-McDonagh M.M, Ficht T.A., 2010. 
"Polymeric particles in vaccine delivery." Curr. Opin. Microbiol. 13: 106-112 . 
Page 24 of 26 
Ross P.J., Sutton C.E., Higgins S., Allen A.C.,Walsh K., Misiak A., Lavelle E.C., 
McLoughlin R.M., Mills K.H., 2013. "Relative Contribution of Th1 and Th17 Cells in 
Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an 515 
Improved Acellular Pertussis Vaccine." PLoS Pathog. 9: e1003264 . 
doi10.1371/journal.ppat.1003264.  
Roush S.W., Murphy T.V., 2007. Vaccine-Preventable Disease Table Working Group. 
"HIstorical comparisons of morbidity and mortality for vaccine-preventable diseases in 
the united states." JAMA 298: 2155-2163. 520 
Santillan D.A., Rai K.K., Santillan M.K., Krishnamachari Y., Salem A.K., Hunter S.K., 
2011 "Efficacy of polymeric encapsulated C5a peptidase–based group B streptococcus 
vaccines in a murine model." Am. J. Obstet. Gynecol. 205: 249.e1-8. doi: 
10.1016/j.ajog.2011.06.024. 
 Higgins S.C., Jarnicki A.G., Lavelle E.C., Mills K.H., 2006. "TLR4 Mediates Vaccine-525 
Induced Protective Cellular Immunity to Bordetella pertussis: Role of IL-17-Producing 
T Cells1." J. Immunol. 177: 7980-7989 . 
Singh D., Somani V.K., Aggarwal S., Bhatnagar R., 2015. "PLGA (85:15) nanoparticle 
based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 
544 infection: A promising alternate to traditional adjuvants." Mol. Immunol. 68 : 272-530 
279 (2015). 
 
 
Figure legends: 
Figure 1 The particle morphology of BSA-loaded PLGA nano/microparticles by SEM. 535 
Figure 2 Effect of NP/MPs formulation on phagocytosis by macrophages. The figure is a 
representative result for confocal laser-scanning microscopy and flow cytometry of n ≥ 2 
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independent experiments. J774.2 cells were incubated with 120 µg/ml soluble BSA-FITC 
antigen (panel B ), BSA-FITC NP/MPs (panel C ) for 1h at 37◦C in an atmosphere of 5% (v/v) 
CO2. Cells treated under identical conditions without incubation with antigen were used as 540 
negative controls (panel A) in all experiments. Uptake of fluorescent antigen was visualised by 
confocal laser-scanning microscopy (panels A-C, scale bars = 15 µm) and quantified by flow 
cytometry (panels D–F). Confocal image stacks of each sample were collected for individual 
emission/detection channels and a composite image formed from data from multi-channels. 
Images were analysed using IMARIS software v7.4.2 (Bitplane, Switzerland) [green, target 545 
protein; blue, nucleus; and red, F-actin of cytoskeleton]. The flow cytometry (panels D–F) 
shows the median fluorescence intensity (MedFI) of the P2 daughter population derived from 
alive cell gated parent population (P1). (For interpretation of the references to color in figure 
legend, the reader is referred to the web version of the article).  
 550 
Figure 3 IgG antibody response from mice immunised with soluble PTd and PTd 
NP/MP. Mice were injected subcutaneously at days 0 and 28 with 0.5 ml volumes of the 
desired formulation (5µg/dose). Mice injected with PBS served as negative controls.  Sera for 
antibody determinations were obtained at four weeks after primary immunisation (grey) and 
two weeks post-boost (black). Results represent the geometric mean antibody for ﬁve mice per 555 
group plus the SEM (error bars).  Insert shows individual response from groups of five mice 
Figure 4 Production of (A) INF-γ and (B) IL-17 from spleen cells from mice at two 
weeks post boost after re-stimulation with heat killed B.pertussis for 48 h. Groups of 
mice were immunized with soluble PTd or PTd NP/MP (5µg/dose) or were given PBS only. 
Spleen cells were obtained on day 42, and the cells from ﬁve mice were pooled. Results 560 
represent the means for duplicate assays with SEM (error bars). 
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Figure 5 Protection of mice against aerosol challenge with B. pertussis. Group of 10 
mice were immunized intraperitoneally on days 0 and 28 with soluble PTd or PTd NP/MP (5 
µg/mouse). Mice injected with PBS served as negative controls. Mice were challenged aerosol 565 
with B. pertussis 18.323 on day 42. Five mice from the PBS control group were sampled at 2 h 
post-challenge for enumeration of bacteria in lungs and tracheas. All remaining mice 
immunized with the desired formulation and mice from the PBS control group were sampled at 
7 days post-challenge. Results represent percentage reduction in CFUs for immunised groups 
compared with PBS group (100%). 570 
 
 
